May 15, 2007PLoS ONEOpen Access

LRP1 Functions as an Atheroprotective Integrator of TGFβ and PDGF Signals in the Vascular Wall: Implications for Marfan Syndrome

View Full Paper

Ask AI

Bookmark

Why the study?

Does rosiglitazone reverse the Marfan-like phenotype and reduce atherosclerosis in smLRP(-) animal models?

Population

LRP1-deficient vascular smooth muscle cell (smLRP(-)) animal models

Design

Preclinical

Authors

PBPhilippe BoucherInserm WLWeiping LiCapital Medical University RMRachel L. MatzInserm

Discussion

Member takes

Implication

LRP1 deletion in VSMC produces Marfan-like aortic disease; leaves open its relevance to human aortopathy and need for clinical studies.

Structured PICO

Does rosiglitazone reverse the Marfan-like phenotype and reduce atherosclerosis in smLRP(-) animal models?

Population

LRP1-deficient vascular smooth muscle cell (smLRP(-)) animal models

Intervention

Rosiglitazone (PPARgamma agonist)

Outcome

Reversal of Marfan-like phenotype, reduction in smooth muscle proliferation, fibrosis, and atherosclerosissurrogate

LRP1 functions as an atheroprotective integrator of TGFβ and PDGF signals, and its deficiency in VSMCs causes a Marfan-like syndrome that can be reversed by rosiglitazone.

Cite This Study

Boucher et al. (2007) studied this question.

synapsesocial.com/papers/6a816ec82bdcf510039cddf4 https://doi.org/10.1371/journal.pone.0000448

View Full Paper

Ask AI

Bookmark

May 15, 2007PLoS ONEOpen Access

LRP1 Functions as an Atheroprotective Integrator of TGFβ and PDGF Signals in the Vascular Wall: Implications for Marfan Syndrome

View Full Paper

Ask AI

Bookmark

Why the study?

Does rosiglitazone reverse the Marfan-like phenotype and reduce atherosclerosis in smLRP(-) animal models?

Population

LRP1-deficient vascular smooth muscle cell (smLRP(-)) animal models

Design

Preclinical

Authors

PBPhilippe BoucherInserm WLWeiping LiCapital Medical University RMRachel L. MatzInserm

Discussion

Member takes

Implication

LRP1 deletion in VSMC produces Marfan-like aortic disease; leaves open its relevance to human aortopathy and need for clinical studies.

Structured PICO

Does rosiglitazone reverse the Marfan-like phenotype and reduce atherosclerosis in smLRP(-) animal models?

Population

LRP1-deficient vascular smooth muscle cell (smLRP(-)) animal models

Intervention

Rosiglitazone (PPARgamma agonist)

Outcome

Reversal of Marfan-like phenotype, reduction in smooth muscle proliferation, fibrosis, and atherosclerosissurrogate

LRP1 functions as an atheroprotective integrator of TGFβ and PDGF signals, and its deficiency in VSMCs causes a Marfan-like syndrome that can be reversed by rosiglitazone.

Cite This Study

Boucher et al. (2007) studied this question.

synapsesocial.com/papers/6a816ec82bdcf510039cddf4 https://doi.org/10.1371/journal.pone.0000448

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark